Piper Sandler Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $33
Benzinga Newsdesk 7 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Piper Sandler analyst Matt O'Brien upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Overweight and raises the price target from $21 to $33.
Piper Sandler analyst Matt O'Brien upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Overweight and raises the price target from $21 to $33.